Allergan announces it is acquiring Bonti Inc, makers of a new neuromodulator, EB-001, that is being developed for both cosmetic and therapeutic use.

EB-001 will be a new player in the neuromodulator market, with the key differences of taking effect within 24 hours and lasting about two to four weeks. Current FDA-approved neuromodulators available in the U.S.—Botox Cosmetic, Dysport and Xeomin—take roughly a week before patients see a reduction of lines and wrinkles and last for a three to six-month period before wearing off.

The product is currently in Phase II clinical trials and contains both an aesthetic (EB-001A) program and a therapeutic (EB-001T) program.

Read the full article at